Articles By Estel Grace Masangkay

  1. Pfizer Links With Merck KGaA In Immuno-Oncology Mega Deal 11/19/2014

    Pfizer announced that it has signed up with German firm Merck KGaA to co-develop and market an investigational anti-PD-L1 treatment for several types of cancer.

  2. Sarepta Kickstarts Eteplirsen Study In Muscular Dystrophy 11/18/2014

    Sarepta Therapeutics announced that it has begun the clinical study of its lead exon-skipping therapeutic candidate eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

  3. Xeris' Hypoglycemia Drug Awarded FDA And EMA Orphan Status 11/17/2014

    Clinical stage, specialty biopharmaceutical company Xeris Pharmaceuticals announced that it has received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for its investigational soluble glucagons as preventive treatment for severe, persistent hypoglycemia in patients with congenital hyperinsulinism (HI).

  4. Encycle Therapeutics Advances Macrocycle Drug For IBD 11/17/2014

    Biotech startup Encycle Therapeutics announced that it has entered into multi-stakeholder collaboration for the development of its lead macrocycle drug for the treatment of inflammatory bowel disease (IBD).

  5. RedHill BioPharma's H. Pylori Drug Snags FDA QIDP Status 11/14/2014

    RedHill BioPharma, an Israeli firm specializing on late clinical-stage drugs for gastrointestinal and inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) status for RHB-105, its Phase 3 Helicobacter pylori (H. pylori) eradication therapy.

  6. GliaCure's Lead Drug For Alzheimer's Fast Tracked By FDA 11/14/2014

    GliaCure, a privately-held biotech firm that develops treatments for neurological and neuropsychiatric disorders based on glial targets, announced that the U.S. Food and Drug Administration (FDA) has awarded Fast Track status to its lead drug GC021109 as treatment for Alzheimer’s disease.

  7. The Medicines Company Launches Carbavance Phase 3 Study 11/12/2014

    The Medicines Company announced that it has launched the Phase 3 trial of its investigational antibiotic Carbavance as treatment for serious bacterial infections due to gram-negative bacteria following the recent enrollment of the trial’s first patient.

  8. Merck Posts Data For Triple-Drug HCV Regimen 11/12/2014

    Merck announced that it will present interim data from the proof-of-concept study investigating the company’s triple-therapy comprised of grazoprevir and elbasvir together with the nucleotide inhibitor sofosbuvir for the Hepatitis C virus (HCV).

  9. Merck And BIND To Develop Nanomeds For Cancer 11/11/2014

    Clinical stage nanomedicine platform company BIND Therapeutics announced that it has signed a joint R&D agreement with Merck to develop novel nanomedicines for oncology.

  10. Janssen To Present Data On Imbruvica At ASH 2014 11/11/2014

    Johnson & Johnson company Janssen R&D reported that it will present new data from its oncology portfolio in over eight diseases at the 56th American Society of Hematology (ASH) Annual Meeting to be held next month in San Francisco, California.